Glioma Clinical Trial
— MACISTOfficial title:
Phase Ib Study of Metformin and Chloroquine in IDH1/2-mutated Patients With Glioma, Intrahepatic Cholangiocarcinoma or Chondrosarcoma
Verified date | January 2020 |
Source | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase Ib, open-label, single-center, non-randomized clinical trial will evaluate the toxicity and efficacy of metformin and chloroquine in isocitrate dehydrogenase 1/2-mutated (IDH1/2MT) patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma.
Status | Completed |
Enrollment | 15 |
Est. completion date | November 18, 2019 |
Est. primary completion date | November 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Presence of a glioma, IHCC or WHO grade = II CS (both newly-diagnosed and refractory/relapsed tumors) 2. Tumor carries a neomorphic D-2HG generating mutation in IDH1 or IDH2 as determined by MS of serum and urine (optional: bile), MRS of the tumor or DNA sequencing of (circulating) tumor material. 3. Measurable lesion according to RECIST 1.1 criteria (see Appendix B) in IHCC and CS patients and RANO criteria (see Appendix C) in glioma patients. 4. ECOG/WHO performance 0-2 (see Appendix D). 5. Age > 18 years. 6. Adequate renal function (creatinine < 150 µmol/L and/ or a creatinine clearance > 60 ml/ L). 7. Adequate liver function (bilirubin < 1.5 times upper limit of normal, ALAT or ASAT < 5.0 times upper limit of normal in case of liver metastases and < 2.5 the upper limit of normal in absence of liver metastases). 8. Adequate bone marrow function (WBC > 3.0 x 109/L, platelets > 100 x 109/L). 9. If patient is eligible for resection, surgery is (already) planned at least 4 weeks away from start study treatment. 10. Mentally, physically, and geographically able to undergo treatment and follow up. 11. Signed informed content obtained prior to treatment. Exclusion Criteria: 1. Pregnancy (positive serum pregnancy test) and lactation. 2. Serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator. 3. Patients who have any severe and/or uncontrolled medical conditions such as: - unstable angina pectoris, - symptomatic congestive heart failure, - myocardial infarction, - cardiac arrhythmias, - pulmonary insufficiency, - epilepsy (interaction with chloroquine), - severe gastrointestinal, neurological or hematological diseases (interaction with chloroquine). 4. 6 months prior to randomization: - serious uncontrolled cardiac arrhythmia, - uncontrolled diabetes as defined by fasting serum glucose >2X ULN, - active or uncontrolled severe infection, including malaria, - cirrhosis, chronic active hepatitis or chronic persistent hepatitis, - severely impaired lung function. 5. Patients that use digoxin, MAO inhibitors, fenylbutazone, oxygenbutazone, gold preparations or cimetidine (known pharmaco interaction with chloroquine) or loop diuretics (known pharmaco interaction with metformin) for which no good alternative is available. 6. Patients that have a known history of alcohol abuse (interaction with metformin). 7. Patients with known glucose-6-phosphate dehydrogenase deficiency, porphyria, myasthenia gravis or ocular/retinal aberrations (interaction with chloroquine). 8. Patients with a known hypersensitivity to metformin or chloroquine. 9. Patients that are lactose intolerant. 10. Use of metformin or chloroquine in the previous 6 months. 11. Long-term use of chloroquine (>5 years or cumulative dose >300 grams) in the past. 12. Use of other anti-cancer therapy (i.e. surgical resection, chemotherapy, targeted therapy, radiation therapy, surgery). Palliative therapy is permitted, such as: - palliative radiotherapy for symptomatic bone metastases; - dexamethasone for symptom relief in patients with glioma and cerebral edema; - non-enzyme inducing antiepileptic drugs (with the exception of topiramate) in patients with glioma and epileptic seizures. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Academic Medical Center | Amsterdam | Noord-Holland |
Netherlands | VU University Medical Center | Amsterdam | Noord-Holland |
Netherlands | Leiden University Medical Center | Leiden | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose of metformin + chloroquine | The maximum tolerated dose is the chloroquine plus metformin dose in which no more than 1 in 3 patients (of a 3+3 dose-escalation schedule) observe serious adverse effects. | 1 year | |
Secondary | Effect of metformin + chloroquine on serum/urine/bile D-2-hydroxyglutarate (D2HG) concentration | D-2HG concentration will be measured by mass spectrometry (MS) in serum/urine/bile, at the beginning and end of the study. | 1 year | |
Secondary | Effect of metformin + chloroquine on intratumoral D2HG concentration | Intratumoral D-2HG concentration will be measured by magnetic resonance spectroscopy (MRS), at the beginning and end of the study. | 1 year | |
Secondary | Effect of metformin + chloroquine on tumor response | Tumor size will be measured using a MRI/CT scan before and after treatment. | 1 year | |
Secondary | Recommended dose of metformin + chloroquine | The recommended dose is the dose of chloroquine plus metformin is the dose level one step below the maximum tolerated dose. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
Enrolling by invitation |
NCT04461002 -
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT03242824 -
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
|
Phase 2 | |
Recruiting |
NCT04186832 -
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
|
N/A | |
Completed |
NCT00424554 -
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
|
Phase 2 | |
Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT02805179 -
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
|
Phase 2 | |
Terminated |
NCT04556929 -
Enhanced Detection in Glioma Excision
|
N/A | |
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Recruiting |
NCT06043232 -
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
|
||
Not yet recruiting |
NCT06043765 -
Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
|
N/A | |
Not yet recruiting |
NCT05025969 -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
|
||
Completed |
NCT02978261 -
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
|
Phase 1 | |
Terminated |
NCT01502605 -
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
|
Phase 1 | |
Completed |
NCT01836536 -
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
|
N/A | |
Completed |
NCT01479686 -
iMRI Guided Resection in Cerebral Glioma Surgery
|
Phase 3 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 |